RGEN

Repligen Challenges Resistance On Increased Volume - 11/12 - 12:10 PM ET

RGEN: To Present At Rodman & Renshaw Investment Conference @ 16:55 ET [delayed] - 11/10 - 03:23 PM ET

Repligen initiates Phase IIb bipolar depression trial - 11/07 - 12:13 PM ET

RGEN: Q2 Earnings Call @ 10:00 ET Today [delayed] - 11/06 - 07:41 AM ET

BRIEF-Repligen reports Q3 results - 11/06 - 07:11 AM ET

Repligen Initiates Phase 2b Clinical Trial of RG2417 in Bipolar Disorder - 11/06 - 07:05 AM ET

Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST - 11/03 - 12:00 PM ET

RGEN: To Present At UBS Global Life Sciences Conference @ 13:00 ET [delayed] - 09/24 - 11:24 AM ET

Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT - 09/17 - 09:30 AM ET

RGEN: Publication of Positive Preclinical Study in Huntington's Disease - 09/16 - 11:52 AM ET

Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntington's Disease Model - 09/16 - 11:19 AM ET

RGEN: Receives $1.125M Research Grant for Friedreich's Ataxia Treatment - 09/04 - 08:45 AM ET

Repligen Receives Research Grants to Support Friedreich's Ataxia Development Program - 09/04 - 07:00 AM ET

RGEN: Q1 Earnings Call @ 11:00 ET Today [delayed] - 08/07 - 08:31 AM ET

RGEN: To Present At BMO Focus on Healthcare Conference @ 10:00 ET [delayed] - 08/06 - 08:28 AM ET

Repligen Schedules August 7 Earnings Call - 07/31 - 08:35 PM ET

Repligen Announces Conference Call of First Quarter Fiscal Year 2009 Results - 07/31 - 10:27 AM ET

Presentation of North America's First Certificate for BS 25999, the New Standard for Business Continuity - 07/08 - 11:31 AM ET

Repligen First in North America to Receive Certification for Business Continuity - 07/08 - 07:50 AM ET

Goldberg Named To Repligen Board - 07/01 - 04:14 PM ET

Page 1 of 4     1  2   3   4      Previous  |  Next

<< Back to Stock Index